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Bver the past 15 years, the association of sleep apnea and
erious medical consequences has slowly entered main-
tream medicine. From a noisy and almost comical condi-
ion to one that is now recognized to be associated with
erious morbidity and mortality, investigators around the
orld are studying the complex relationships between sleep
nd the neurologic, pulmonary, endocrine, and cardiovas-
ular systems. As the evidence has mounted, screening and
reatment of sleep apnea has been incorporated into clinical
ractice guidelines and reports for several serious medical
onditions including, among others, hypertension (Joint
ational Committee 7) (1), heart failure (American College
f Cardiology/American Heart Association [ACC/AHA])
2), pulmonary arterial hypertension (ACC/AHA) (3), and
ype 2 diabetes mellitus (International Diabetes Federation)
4). This effort has culminated in an ACC/AHA scientific
tatement focused exclusively on sleep apnea and cardiovas-
ular disease. This statement reviews the known mecha-
isms as well as the association of various forms of sleep
pnea with hypertension, heart failure, stroke, arrhythmias,
yocardial infarction and ischemia, pulmonary arterial hy-
ertension, and end-stage renal disease. It concludes with a
all for more study to understand mechanisms, associations,
nd the impact of treatment of sleep apnea on patients with
nd at risk for cardiovascular disease (5).
See page 1706
Unfortunately, studying sleep apnea in clinical popula-
ions is a significant challenge. Obstructive sleep apnea is
ssociated with obesity, which can mask the impact of sleep
pnea on risk factors and cardiovascular disease. In addition,
leep apnea is associated with multiple comorbidities, in-
luding cardiovascular disease, diabetes, and the metabolic
yndrome. Central sleep apnea is associated with the pres-
nce of heart failure and stroke. Establishing causality or
ven which condition came first can be elusive, requiring
arge populations followed up over long periods of time. It
s for this reason that studies focusing on pathophysiology
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Cardiovascular Division, Department of Medicine, University of Penn-n
ylvania School of Medicine, Philadelphia, Pennsylvania. Dr. Goldberg has received
esearch funding from ResMed, Inc.ay help to unravel the connections and better inform the
evelopment of clinical trials.
Sleep apnea occurs primarily in 2 forms: obstructive and
entral. Obstructive sleep apnea results from a complete or
artial collapse of the pharynx leading to respiratory effort
ut no airflow into the lungs (6). Central sleep apnea results
rom a lack of neurologic respiratory drive leading to no
espiratory effort and no airflow into the lungs (7). Further
omplicating study in this area is that many persons display
ixed apneas, having some features of both forms, and
thers may switch from one form of sleep apnea to another.
Heart failure, both systolic and with preserved left ven-
ricular function, is associated with sleep apnea. Several
tudies have estimated that the presence of obstructive sleep
pnea ranged from 11% to 37%, and central sleep apnea may
e present in as many as 40% of patients with systolic heart
ailure (5). These findings suggest a large population at risk
nd a huge potential public health benefit from treating
leep apnea if treatment is shown to improve clinical
utcomes.
The paper by Gottlieb et al. (8) in this issue of the Journal
escribes the relationship between sleep apnea and brain
B-type) natriuretic peptide (BNP) in subjects with symp-
omatic systolic heart failure. The population of subjects
ncluded some with obstructive sleep apnea and others with
entral sleep apnea. The subjects were very well treated,
eceiving guideline-mandated pharmacologic therapies for
heir systolic heart failure, with nearly everyone on both a
eta-blocker and angiotensin-converting enzyme inhibitor
r angiotensin-receptor blocker. The investigators fre-
uently measured serum BNP and correlated these mea-
urements with measured variables during a series of over-
ight sleep studies.
It has been shown in both humans and animal models
hat obstructive sleep apnea has a significant hemodynamic
mpact on the heart. During an obstructive apnea event,
here is inspiratory effort against the closed airway. This
auses changes in intrathoracic pressure that increases left
entricular afterload, which in theory would cause increases
n myocardial pressure. Simultaneously, there are surges of
drenergic activity that increase heart rate and blood pres-
ure and may also be responsible for increased inflammatory
arkers. In this setting of increased afterload and adrenergic
verdrive, one would expect an increase in the release of
NP (5,9). On the contrary, during a central apnea, there is
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ncrease in adrenergic activity (10). In this instance, one
ight hypothesize that BNP levels would not change,
specially if the pathway was due to the mechanical impact
f pressure and volume changes in the left ventricle.
The surprising result of this investigation (8) is that
nstead of being correlated with mechanical events, serum
NP levels were associated with hypoxia. This finding was
urther validated by comparing the group of subjects with
bstructive apnea against those with central apnea. In both
nstances, BNP correlated with hypoxia but not with the
echanical hemodynamic consequences of airway obstruc-
ion. One unifying hypothesis is that the adrenergic surges
een in both obstructive and central sleep apnea can acutely
ause mechanical or neurohormonal changes leading to
ncreased BNP levels. In this investigation, BNP levels rose
espite all of the subjects being administered a beta-blocker,
mplying that this hypothesis may be incorrect or that
eta-blockers at clinical doses are ineffective at blunting the
mpact of these adrenergic surges. Unfortunately, the ad-
inistration of nocturnal oxygen in this study did not
ppear to change BNP levels, but the number of subjects
valuated was small and the population was heterogeneous.
Perhaps the most important result from this study by
ottlieb et al. (8) is the direct correlation between changes
n serum BNP, a potent prognostic marker in heart failure,
nd hypoxia in sleep apnea. This finding should add to the
vidence that sleep apnea in any form is a reasonable
herapeutic target to potentially improve outcomes in people
ith systolic heart failure. In addition, this study suggests
hat beta-blockers are not completely able to protect against
he impact of sleep apnea on the cardiovascular system and
hat more complex mechanisms may be responsible for the
linical consequences of the combination of heart failure and
leep apnea.
There is unequivocal evidence linking sleep apnea to
ardiovascular disease and other chronic illnesses (5). The
urrent investigation (8) highlights the importance of mech-
nistic studies to help inform the development of clinical
rials in the growing population of people with sleep apnea.
ssuming the results can be replicated, a potential target for
reatment would be nocturnal hypoxia. In addition, differ-
ntiating between central or obstructive sleep apnea may be
ess important, but rather the presence of hypoxia may be
nough to warrant treatment. The diagnosis and treatment
f sleep apnea in any form can be challenging, but well-
K
nducated and energized clinicians can motivate patients to
e successful. It is clear that large-scale multicenter clinical
utcome trials evaluating sleep apnea treatments for patients
ith heart failure treated with modern therapies are critical
o define the appropriate interventions needed to address
his potential therapeutic target.
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